J. B. Shepherd

Q: What Schools Are Affiliated With J. B. Shepherd

J. B. Shepherd is affiliated with the following schools: University of Glasgow, University of Helsinki

J. B. Shepherd's AcademicInfluence.com Rankings

J. B. Shepherd

Philosophy

#4653

World Rank

#7251

Historical Rank

Logic

#2066

World Rank

#2966

Historical Rank

philosophy Degrees

Download Badge

Philosophy

J. B. Shepherd's Degrees

Doctorate Medicine Stanford University

Why Is J. B. Shepherd Influential?

(Suggest an Edit or Addition)

(See a Problem?)

J. B. Shepherd's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (1995) (5842)
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. (2008) (4914)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. (2005) (3308)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial (2002) (3200)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. (1995) (2355)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials (2010) (1770)
Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study (2003) (1584)
West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials (1996) (1291)
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. (2005) (1195)
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial (2009) (989)
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease (2008) (925)
Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study (2001) (896)
Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS) (2001) (859)
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). (1998) (810)
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials (2009) (781)
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. (2009) (695)
Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study (2007) (579)
A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. (1997) (578)
Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. (1994) (551)
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies (2008) (499)
The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. (1999) (482)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial (2003) (441)
Effects of dietary polyunsaturated and saturated fat on the properties of high density lipoproteins and the metabolism of apolipoprotein A-I. (1978) (433)
Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project (2000) (422)
Lipoprotein heterogeneity and apolipoprotein B metabolism. (1997) (410)
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes (2006) (409)
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study (2006) (383)
Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease (2004) (377)
Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. (2004) (376)
Effects of saturated and polyunsaturated fat diets on the chemical composition and metabolism of low density lipoproteins in man. (1980) (354)
Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. (1980) (333)
Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM (1997) (326)
Lipoprotein Subfraction Concentrations in Preeclampsia: Pathogenic Parallels to Atherosclerosis (1997) (326)
Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. (1984) (315)
Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment: Individual Patient Meta-Analysis of 13 677 Subjects (2005) (311)
Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project (2001) (300)
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. (2008) (295)
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. (1999) (285)
Long-term follow-up of the West of Scotland Coronary Prevention Study. (2007) (280)
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. (2007) (266)
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C* (2004) (265)
Pravastatin and cognitive function in the elderly. Results of the PROSPER study (2009) (255)
Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. (1979) (254)
Postprandial lipemia, fenofibrate and coronary artery disease. (1990) (248)
Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. (1996) (236)
Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. (1990) (236)
Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. (2000) (232)
Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial (2010) (227)
Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein. (1997) (219)
Blood Rheology, Cardiovascular Risk Factors, and Cardiovascular Disease: The West of Scotland Coronary Prevention Study (2000) (215)
The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin (1997) (209)
Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity. (1994) (208)
Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease (2005) (200)
Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. (1996) (200)
Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. (1998) (196)
Coronary Heart Disease in Patients With Low LDL-Cholesterol: Benefit of Pravastatin in Diabetics and Enhanced Role for HDL-Cholesterol and Triglycerides as Risk Factors (2002) (193)
Familial combined hyperlipidaemia linked to the apolipoprotein AI–CIII–AIV gene cluster on chromosome 11q23q–q24 (1991) (191)
Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy. (1983) (187)
Metabolic basis of hypotriglyceridemic effects of insulin in normal men. (1997) (187)
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. (2008) (176)
Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. (1995) (168)
Receptor-mediated low density lipoprotein catabolism in man. (1979) (167)
Effect of pravastatin in people with diabetes and chronic kidney disease. (2005) (163)
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases (2007) (155)
Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. (1991) (153)
The role of small, dense low density lipoprotein (LDL): a new look. (2000) (151)
Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. (1988) (151)
Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women. (1995) (145)
Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation (2011) (145)
Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. (1995) (140)
Testing cognitive function in elderly populations: the PROSPER study (2002) (139)
Association Between Apolipoprotein E4 and Cognitive Decline in Elderly Adults (2007) (136)
Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution (1993) (133)
Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. (1993) (131)
Effects of cholestyramine on receptor-mediated plasma clearance and tissue uptake of human low density lipoproteins in the rabbit. (1980) (131)
C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) (2007) (130)
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. (2007) (130)
Effects of simvastatin on apoB metabolism and LDL subfraction distribution. (1993) (130)
Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects. (1994) (128)
Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM (1990) (127)
Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance. (1995) (122)
Plasma Lipoproteins and Apolipoproteins as Predictors of Cardiovascular Risk and Treatment Benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) (2005) (122)
Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study (2007) (120)
Unraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approach. (2009) (120)
Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. (1997) (117)
Radioiodination of human low density lipoprotein: a comparison of four methods. (1976) (117)
Lipoproteins in Health and Diseases (1999) (116)
The hepatobiliary axis and lipoprotein metabolism: effects of bile acid sequestrants and ileal bypass surgery. (1982) (112)
Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events? (2009) (109)
The Relationship between Serum Cholesterol and Serum Thyrotropin, Thyroxine and Tri-Iodothyronine Concentrations in Suspected Hypothyroidism (1990) (107)
Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. (1982) (105)
Associations of indices of adiposity with atherogenic lipoprotein subfractions (1998) (104)
Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel (2005) (103)
Lipid and lipoprotein concentrations in pregnancies complicated by intrauterine growth restriction. (1999) (101)
Cholesterol feeding increases low density lipoprotein synthesis. (1983) (100)
Polymorphisms in the gene coding for cholesteryl ester transfer protein are related to plasma high-density lipoprotein cholesterol and transfer protein activity. (1990) (95)
Fenofibrate Reduces Low Density Lipoprotein Catabolism in Hypertriglyceridemic Subjects (1985) (94)
Low-density lipoprotein metabolism in the nephrotic syndrome. (1990) (93)
Lipids and CVD management: towards a global consensus. (2005) (93)
Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. (1991) (92)
Immunological assays of apolipoproteins in plasma: methods and instrumentation. (1990) (90)
Human Plasma Lipoproteins (1989) (89)
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. (2002) (89)
Leptin Predicts Diabetes but Not Cardiovascular Disease (2009) (88)
Low density lipoprotein metabolism in a family of familial hypercholesterolemic patients. (1976) (86)
The effects of cholestyramine on high density lipoprotein metabolism. (1979) (86)
Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. (1984) (85)
Effect of pravastatin on the development of diabetes and adiponectin production. (2008) (83)
Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. (2002) (81)
Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. (1997) (81)
Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. (1995) (79)
Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. (1996) (79)
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. (2004) (78)
Genetic variation in the interleukin-1 beta-converting enzyme associates with cognitive function. The PROSPER study. (2008) (78)
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. (2008) (76)
Catabolic rate of low density lipoprotein is influenced by variation in the apolipoprotein B gene. (1988) (74)
A Longitudinal Study of the Relationships between Haemostatic, Lipid, and Oestradiol Changes during Normal Human Pregnancy (1999) (73)
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study (2010) (72)
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. (2008) (72)
Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins. (1995) (72)
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. (2008) (71)
The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins. (1983) (70)
Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study (2000) (69)
Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. (1993) (66)
The in vitro interaction of human apolipoprotein A-I and high density lipoproteins. (1977) (66)
Dynamic properties of human high density lipoprotein apoproteins. (1978) (65)
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). (2010) (65)
Effect of saturated and polyunsaturated fat diets on the composition and structure of human low density lipoproteins (1980) (62)
The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. (2011) (61)
Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). (2002) (60)
Thyroid dysfunction and hypercholesterolaemia in the general population of Glasgow, Scotland. (1988) (60)
Reduced Glomerular Filtration Rate and Its Association with Clinical Outcome in Older Patients at Risk of Vascular Events: Secondary Analysis (2009) (59)
The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. (1995) (59)
Effects of pregnancy and lactation on plasma lipid and lipoprotein concentrations, lipoprotein composition and post-heparin lipase activities in Shetland pony mares. (1993) (58)
Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. (2009) (58)
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003. (2003) (57)
Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease (2004) (57)
Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. (2008) (57)
Metabolism of apolipoproteins A‐I and A‐ll and its influence on the high density lipoprotein subfraction distribution in males and females (1978) (56)
Metabolic heterogeneity in very low-density lipoproteins. (1987) (56)
International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. (1999) (56)
Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia. (2000) (55)
Mechanism of action of fibrates. (1993) (55)
Plasma lipids, lipoproteins and post-heparin lipases in ponies with hyperlipaemia. (1992) (54)
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies (2009) (54)
Apolipoprotein B metabolism in normal, type IV and type V hyperlipoproteinemic subjects. (1980) (53)
Prevention of cardiovascular disease in general practice: a proposed model. (1986) (53)
A comparison of two methods to investigate the metabolism of human apolipoproteins A-I and and A-II. (1978) (53)
Assessing Risk Prediction Models Using Individual Participant Data From Multiple Studies (2013) (52)
Receptor-independent catabolism of low density lipoprotein. Involvement of the reticuloendothelial system. (1982) (52)
Plasma lipid abnormalities in retinitis pigmentosa and related conditions. (1983) (52)
Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. (1986) (52)
Effects of ciprofibrate on LDL metabolism in man. (1994) (51)
Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly[S] (2010) (51)
Does statin monotherapy address the multiple lipid abnormalities in type 2 diabetes? (2005) (50)
The relationship between the cholesterol content and subfraction distribution of plasma high-density lipoproteins. (1980) (50)
Who should receive a statin these days? Lessons from recent clinical trials (2006) (48)
The role of the exogenous pathway in hypercholesterolaemia (2001) (48)
Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism. (1995) (48)
Association Between ADAMTS1 Matrix Metalloproteinase Gene Variation, Coronary Heart Disease, and Benefit of Statin Therapy (2008) (47)
Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs (2002) (47)
The isolation, characterisation and quantification of the equine plasma lipoproteins. (1991) (46)
Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial (2010) (46)
Genetic variation in the cholesteryl ester transfer protein and apolipoprotein A-I genes and its relation to coronary heart disease in a Sri Lankan population. (1990) (46)
Concentration and distribution of human plasma apolipoprotein E. (1981) (46)
Very low density and low density lipoprotein subfractions in type III and type IV hyperlipoproteinemia. Chemical and physical properties. (1979) (45)
Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation (2008) (45)
Genetic Variation in the Interleukin‐10 Gene Promoter and Risk of Coronary and Cerebrovascular Events (2007) (45)
Mechanism of action of bile acid sequestrants and other lipid-lowering drugs. (1989) (44)
Effect of saturated and unsaturated fat diets on molecular species of phosphatidylcholine and sphingomyelin of human plasma lipoproteins. (1981) (44)
Measures to assess the prognostic ability of the stratified Cox proportional hazards model (2009) (44)
Activation of Hemostasis and Decline in Cognitive Function in Older People (2010) (43)
International Comparison of Awareness and Attitudes Towards Coronary Risk Factor Reduction: The HELP Study (1997) (43)
Plasma triglyceride and low density lipoprotein metabolism (1992) (43)
Response of plasma low density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause (1993) (43)
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics (2002) (42)
Sequential changes in plasma lipoproteins and body fat composition during polyunsaturated fat feeding in man (1980) (41)
Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers (2014) (40)
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study (2009) (38)
Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia. (1980) (38)
Asp92Asn Polymorphism in the Myeloid IgA Fc Receptor Is Associated With Myocardial Infarction in Two Disparate Populations: CARE and WOSCOPS (2006) (38)
Measurement of receptor-independent lipoprotein catabolism using 1,2 cyclohexanedione-modified low density lipoprotein. (1982) (36)
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. (2010) (36)
The Xba1 polymorphism of the apolipoprotein B gene influences the degradation of low density lipoprotein in vitro. (1989) (36)
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. (2011) (36)
Radioimmunoassay for human plasma apolipoprotein B. (1976) (35)
Biogerontology: Mechanisms and Interventions (2007) (35)
Effect on saturated and unsaturated fat diets on lipid profiles of plasma lipoproteins. (1982) (35)
The European Atherosclerosis Research Study (EARS): design and objectives. (1994) (35)
The fibrates in clinical practice: focus on micronised fenofibrate. (1994) (34)
Prevention of coronary heart disease in clinical practice: a commentary on current treatment patterns in six European countries in relation to published recommendations. (1996) (34)
Statins : The HMG CoA reductase inhibitors in perspective (2003) (33)
Effect of heparin-stimulated plasma lipolytic activity on VLDL APO B subclass metabolism in normal subjects. (1999) (33)
Comparison of immunonephelometry and electroimmunoassay for estimation of plasma apolipoprotein A-I. (1980) (33)
Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). (2010) (32)
Metabolism of apolipoprotein A-I in healthy young adults. (1978) (32)
KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly. (2011) (32)
Preventing coronary artery disease in the West of Scotland: implications for primary prevention. (1998) (31)
The effect of testosterone replacement on plasma lipids and apolipoproteins (1989) (31)
Contribution of the Receptor Pathway to Low Density Lipoprotein Catabolism in Humans: New Methods for Quantitation (1984) (31)
Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia. (1993) (30)
Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. (2011) (30)
Mutations in the HFE Gene and Cardiovascular Disease Risk: An Individual Patient Data Meta-Analysis of 53 880 Subjects (2008) (30)
Coronary venous lipid peroxide concentrations after coronary angioplasty: correlation with biochemical and electrocardiographic evidence of myocardial ischaemia (1992) (29)
Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. (1996) (29)
Effects of 1,2-cyclohexanedione modification on the metabolism of very low density lipoprotein apolipoprotein B: potential role of receptors in intermediate density lipoprotein catabolism. (1985) (28)
Plasma lipid transport in the horse (Equus caballus). (1993) (28)
An StuI RFLP at the human cholesteryl ester transfer protein (CETP) locus. (1989) (28)
Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group. (1994) (28)
A Comparison of Commercial Kits for the Measurement of Lipoprotein(a) (1991) (27)
Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. (2001) (27)
Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study. (2001) (27)
Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions. (1999) (27)
The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS). (2000) (26)
Receptor-mediated catabolism and tissue uptake of human low density lipoprotein in the cholesterol-fed, atherosclerotic rabbit. (1982) (26)
Dyslipidaemia in diabetic patients: time for a rethink (2007) (26)
Regulation of small dense LDL concentration in Korean and Scottish men and women. (2002) (26)
An investigation of the relationships between body condition and plasma lipid and lipoprotein concentrations in 24 donkeys (1990) (25)
Identifying patients at risk for coronary heart disease: treatment implications. (1998) (25)
High-density lipoprotein subfractions as measured by differential polyanionic precipitation and rate zonal ultracentrifugation. (1982) (24)
Selective measurement of lipoprotein lipase and hepatic triglyceride lipase in heparinized plasma from horses. (1992) (24)
Receptor-independent low-density lipoprotein catabolism. (1986) (23)
Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome. (1992) (23)
Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies (2010) (23)
Pharmacological approaches to the modulation of plasma cholesterol. (1988) (23)
Combined drug therapy for familial hypercholesterolemia. (1980) (22)
Metabolism of HDL apolipoprotein A-I and A-II in Type 1 (insulin-dependent) diabetes mellitus (1992) (22)
Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. (2012) (21)
Post‐prandial lipoprotein metabolism in nephrotic syndrome (1992) (21)
Influence of etofibrate on low density lipoprotein metabolism. (1988) (20)
The ins/del polymorphism in the signal sequence of apolipoprotein B has no effect on lipid parameters. (1993) (20)
Restriction fragment length polymorphisms in the Apo B gene in relation to coronary heart disease in a southern Asian population. (1991) (19)
Statin Therapy in the Elderly (2004) (19)
Genetic variants in the KIF6 region and coronary event reduction from statin therapy (2010) (19)
Probucol reduces plasma lipid peroxides in man. (1991) (19)
Lipoprotein metabolism. An overview. (1994) (18)
Effects of cholesterol and lipoproteins on aldosterone secretion by bovine zona glomerulosa cells. (1989) (18)
Lipoprotein metabolism in familial hypercholesterolemia. (1989) (18)
Management of hyperlipidaemia. Why, when and how to treat. (1997) (18)
Plasma apolipoprotein A levels in healthy human adults. (1975) (17)
Rosuvastatin for primary prevention in older individuals with high C-reactive protein and low LDL levels: exploratory analysis of a randomized trial (2010) (17)
Low density lipoprotein metabolism. (1988) (17)
Fibric acid derivatives (1991) (17)
Association of the 719Arg variant of KIF6 with both increased risk of coronary events and with greater response to statin therapy. (2008) (17)
Combined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia. (2003) (17)
Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia. (1989) (17)
Ultracentrifugal subfractionation of high-density lipoprotein. (1984) (17)
From best evidence to best practice - what are the obstacles? (1999) (17)
Lipoprotein receptors and atherosclerosis. (1986) (16)
Inherited hyperchylomicro‐naemia in the cat: Lipoprotein lipase function and gene structure (1992) (16)
Blood rheology and outcome in the West of Scotland Coronary Prevention Study (1997) (16)
Apolipoprotein B overproduction by the perfused liver of the St. Thomas' mixed hyperlipidemic (SMHL) rabbit. (1999) (15)
The statin era: in search of the ideal lipid regulating agent (2001) (15)
Action of danazol on plasma lipids and lipoprotein metabolism. (1994) (15)
Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly (2009) (15)
Effects of dietary saturated and polyunsaturated fat on the metabolism of apolipoproteins A-I and B. Study of a patient with type IIb hyperlipoproteinaemia. (1978) (15)
Lipid metabolism in retinitis pigmentosa. (1987) (14)
In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107-->0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency. (1997) (14)
High density lipoprotein metabolism in the horse (Equus caballus). (1993) (13)
Sensitive Mass Spectrometry Techniques for Measuring Metabolism of Human Apolipoprotein B In Vivo (1994) (13)
Raising HDL-cholesterol and lowering CHD risk: does intervention work? (2005) (13)
Effects of cholestyramine and acipimox on subf ractions of plasma low density lipoprotein. Studies in normolipidaemic and hypercholesterolaemic subjects (1992) (13)
Regression of coronary atherosclerosis: is it possible? (1988) (13)
Comparative chemistry, pharmacology and mechanism of action of the statins (1999) (13)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995. (2004) (13)
Lipid transport through the plasma: the metabolic basis of hyperlipidaemia. (1987) (12)
Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study). (2016) (12)
Lipoprotein metabolism: an overview. (1992) (12)
Chemical and kinetic study of the lipoproteins in abetalipoproteinaemic plasma. (1978) (12)
Effects of Dietary-Fat Saturation on the Composition of Very-Low-Density Lipoproteins and on the Metabolism of their Major Apoprotein, Apolipoprotein B (1978) (11)
Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia. (1990) (11)
Profiling risk and new therapeutic interventions: looking ahead. (1998) (11)
The reticuloendothelial system and low density lipoprotein metabolism in the rabbit. (1982) (11)
Danazol and plasma lipoprotein metabolism (1995) (10)
Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy* (2004) (10)
A tale of two trials: The West of Scotland Coronary Prevention Study and the Texas Coronary Atherosclerosis Prevention Study. (1998) (10)
Preventing the next event in the elderly: the PROSPER perspective. (2003) (10)
Statin therapy in the elderly: does it make good clinical and economic sense? (2003) (10)
Diagnosis of type III hyperlipoproteinemia by chromatography of plasma lipoproteins on columns containing agarose. (1975) (10)
Frequency of the XbaI, EcoRI, PvuII and MspI polymorphisms of the apolipoprotein B gene in relation to hypercholesterolaemia in the general population. (1993) (10)
Metabolic syndrome and diabetes mellitus. (2004) (10)
Tomorrow's world: atherosclerosis in the year 2000. (1997) (9)
Apolipoprotein B metabolism in man. (2009) (9)
Lymphotoxin-alpha C804A polymorphism is a risk factor for stroke. The PROSPER study (2008) (9)
International comparison of awareness and attitudes towards coronary risk factor reduction: the HELP study. Heart European Leaders Panel. (1997) (9)
Effect of Drugs on High Density Lipoprotein Metabolism (1980) (8)
The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial. (2001) (8)
Receptor-independent low-density lipoprotein catabolism. Evaluation of 2-hydroxyacetaldehyde-treated lipoprotein as a probe for its measurement. (1984) (8)
A longitudinal study of plasma n-3 fatty acid levels in a family with X-linked retinitis pigmentosa. (1990) (8)
A monoclonal-antibody-based immunoradiometric assay for apoprotein B in low-density lipoprotein. (1985) (8)
Low-density lipoprotein metabolism following renal transplantation. (1985) (8)
VLDL and LDL turnover: methods and clinical application (1992) (8)
Lipoprotein Metabolism (2012) (8)
Effect of cholestyramine on low-density lipoproteins. (1980) (8)
A review of the unique features of HDL apoproteins (1979) (7)
The cost-effectiveness of preventing initial coronary events with pravastatin (1997) (7)
Low-density lipoprotein receptor pathway in man: its role in regulating plasma low-density lipoprotein levels (1983) (7)
Diagnosis of dyslipoprotein aemia by molecular sieve chromatography. (1976) (7)
Rosuvastatin significantly improves lipid parameters and ability to achieve low-density lipoprotein cholesterol goals compared with pravastatin (2003) (7)
Unraveling the Directional Link between Adiposity and Inflammation: A Bidirectional Mendelian Randomization Approach. (2009) (7)
Low Density Lipoprotein Uptake by Tumours (1982) (7)
The prosper design. A prospective study of pravastatin in the elderly at risk (1999) (7)
Current concepts in the treatment of familial hypercholesterolaemia. (1995) (6)
A prospective study of pravastatin in the elderly at risk: new hope for older persons. (2004) (6)
Statins: is there a need for alternative or adjunctive therapy? (1995) (6)
The metabolic syndrome is an independent predictor of cardiac events in WOSCOPS males (2003) (6)
Lipid lowering: statins and the future (2000) (6)
Very low density lipoprotein apolipoprotein B metabolism in humans (1988) (6)
Further epidemiological studies on lipid metabolism in retinitis pigmentosa. (1989) (5)
Prospective pravastatin pooling project: Relative risk reduction by baseline HDL and TG concentrations (2000) (5)
Low-Density-Lipoprotein Metabolism in Type n Hyperlipoproteinaemia (1976) (5)
A call to action. (1998) (5)
1.P.139 The cost-effectiveness of preventing initial coronary events with pravastatin: Results of the West of Scotland coronary prevention study economic analysis (1997) (5)
The effect of hypolipidaemic drugs on subfractions of plasma low density lipoprotein (1990) (5)
Models and mechanisms in very low density lipoprotein metabolism (1985) (5)
Cholesterol reduction in the prevention of coronary heart disease: therapeutic rationale and guidelines. The British Hyperlipidaemia Association. (1993) (5)
Lipoprotein metabolism in lipase deficient states: studies in primary and secondary hyperlipidaemia. (1993) (5)
Lipids in health and disease. (2004) (5)
Preferential binding of small, dense LDL to human arterial proteoglycan (1994) (5)
Equine plasma lipoproteins: comparative lessons. (1991) (5)
[Prevention of coronary disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology (ESC), European Atherosclerosis Society (EAS) and European Society of Hypertension (ESH)]. (1995) (5)
Plasma lipid measurement (1990) (4)
Pharmacological modification of lipoprotein metabolism. (1987) (4)
Prevention of heart disease: is LDL reduction the outcome of choice? No, there is more. (1998) (4)
Cholesterol lowering with statins: how WOSCOPS confounded the skeptics. (2007) (4)
An increased incidence of apolipoprotein E2/E2 and E4/E4 in retinitis pigmentosa (1993) (4)
Metabolic Basis of the Atherogenic Lipoprotein Phenotype (1995) (4)
Establishing the metabolic basis of equine hyperlipidaemia (1990) (4)
Prospective study of pravastatin in the elderly at risk: Vascular risk profile of the prosper recruits (2000) (4)
Statin therapy in clinical practice: new developments. (1995) (4)
Evidence for Defect of Receptor-Mediated Low-Density Lipoprotein Catabolism in Familial Hypercholesterolaemia In Vivo (1980) (3)
The Anatomy of a Clinical Trial (2002) (3)
RISK FACTOR MODIFICATION EXTENDS THE BENEFIT OF CORONARY ARTERY REVASCULARISATION PROCEDURES (1999) (3)
Diabetes in tomorrow's world: dark clouds do have silver linings (2002) (3)
Atherogenicity of Triglyceride-Rich Lipoproteins: Clinical Aspects (1993) (3)
Special report: Highlights of the 75th European Atherosclerosis Society congress. (2005) (3)
11 – Low Density Lipoprotein Receptor Activity in Man (1982) (3)
The influence of dietary-fat saturation on the metabolism of apolipoproteins A-I, B and C in a type IIb hyperlipoproteinaemic subject (1978) (3)
An Overview of Lipoprotein Metabolism (1987) (3)
Cholesterol, lipoproteins and atherosclerosis (1990) (3)
Atherosclerosis in perspective: the pathophysiology of human cholesterol metabolism (1992) (3)
Plasma lipids in retinitis pigmentosa (1987) (3)
Lipoprotein Metabolism and Atherogenesis (2000) (3)
Lipid-lowering--translating evidence into benefits. (2002) (3)
Statins for primary prevention: strategic options to save lives and money. (2004) (3)
Abstract 3731: Intensive Lipid Lowering with Atorvastatin is Associated with Significant Cardiovascular Benefits in Patients with and without Chronic Kidney Disease: The Treating to New Targets (TNT) Study (2006) (2)
Obesity, metabolic syndrome and cardiovascular risk (2003) (2)
The pathophysiology of cholesterol metabolism in man (1985) (2)
The metabolism off apo B containing lipoproteins in a patient with hepatic lipase deficiency (1988) (2)
1.P.94 Characterisation of lipoprotein metabolism in the froxfield mixed hyperlipidaemic rabbit (1997) (2)
Triglycerides and coronary risk. (1996) (2)
The statin era in cardiovascular medicine: what's next? (2001) (2)
Drug therapy for atherosclerosis. (1993) (2)
Lipoprotein metabolism and cardiovascular disease. (1987) (2)
Abstract 814: CRP and Risk of Vascular Events in PROSPER (2006) (2)
Cholesterol‐lowering Agents and their Use (2003) (2)
Affairs of the heart: cholesterol and coronary heart disease risk. (1991) (2)
Statins for Primary Prevention: Strategic Options to Save Lives and Money (2004) (2)
Apolipoprotein (APO) B DNA polymorphism associated with differences in LDL metabolism (1987) (2)
4.P.231 Metabolism of triglyceride-rich lipoproteins determines occurrence of atherogenic LDL phenotype (1997) (2)
Abstract 848: Improvement in Estimated Glomerular Filtration Rate With Atorvastatin in Patients With Metabolic Syndrome: The Treating to New Targets Study (2009) (1)
The Reticuloendothelial System and Low Density Lipoprotein Metabolism (1986) (1)
Genetic and environmental modulation of low-density lipoprotein catabolism. (1990) (1)
Do statins reduce the risk for diabetes by improving exercise capacity? Response (2001) (1)
asymptomatic peripheral arterial disease and antioxidants in patients with diabetes and randomised placebo controlled trial of aspirin factorial disease and diabetes (POPADAD) trial: The prevention of progression of arterial (2008) (1)
Reduction in C-Reactive Protein and Low-Density Lipoprotein Cholesterol and Cardiovascular Event Rates After Initiation of Rosuvastatin: A Prospective Study of the justification for the Use of Statins in Prevention: An Intervention, Trial Evaluating Rosuvastatin Trial (2009) (1)
PO16-439 COST-EFFECTIVENESS OF INTENSIVE LIPID-LOWERING TREATMENT IN SECONDARY CARDIOVASCULAR PREVENTION IN SPAIN AND GERMANY (2007) (1)
The low-density-lipoprotein receptor pathway in familial hypercholesterolaemia: its role in pathogenesis and its response to therapy. (1983) (1)
LDL subfractions in non-insulin dependent diabetes mellitus (1993) (1)
Chapter 3. Lipoprotein Metabolism (1989) (1)
Diabetic dyslipidemia and atherosclerosis. (1994) (1)
Erratum: Prediction of cardiovascular events in statin-treated patients by lipid and non-lipid biomarkers (Journal of the American College of Cardiology (2011) 57 (63-69)) (2013) (1)
Metabolic syndrome and diabetes mellitus - Response. (2004) (1)
Effects of Lipid-Lowering Drugs on High Density Lipoprotein Structure and Metabolism (1987) (1)
Dementia and statins [1] (multiple letters) (2001) (1)
The effect of pharmacological agents on low density lipoprotein subfractions (1995) (1)
1.P.153 Influence of pravatatin and plasma lipids on clinical events, in the West of Scotland Coronary Prevention Study (WOSCOPS) (1997) (1)
Primary prevention of coronary heart disease with statins (2004) (1)
Poster abstractLDL subfraction metabolism in young healthy males (1994) (1)
Predictors of glucose intolerance (GI) in the West of Scotland Coronary Prevention Study (WOSCOPS) (2000) (1)
Statins and blood pressure. (2008) (1)
CVB5 Preventing Cardiovascular Disease: Is Primary Prevention with Pravastatin Worth the Money? (1998) (1)
The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. (2002) (1)
The role of the monocyte/macrophage system in lipoprotein metabolism. (1984) (1)
An investigation of the defect in type III hyperlipoproteinemia using agarose column chromatography. (1978) (1)
A longitudinal study of the relationship between lipid, haemostatic and hormonal changes during normal human pregnancy (1998) (1)
Monotherapy vs combination therapy for dyslipidemia in the elderly. (2008) (1)
Guidelines for clinical use of the statins (2003) (1)
EFFECT OF PRAVASTATIN IN PEOPLE WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS: PD.8 (2005) (1)
4.W23.5 Is insulin regulation of VLDL production defective in insulin resistance (1997) (1)
The hyperlipidaemia of normal pregnancy (1995) (1)
Low-density-lipoprotein metabolism in type II hyperlipoproteinaemia. (1976) (1)
Metabolism of apolipoprotein B in primary moderate hypercholesterolaemia: effects of acipimox and cholestyramine therapy. (1995) (1)
Meeting Summary Ninth Annual European Lipoprotein Conference (2005) (1)
Chapter 1. Lipoproteins in Health and Disease: Lipoprotein Nomenclature and the Classification of Hyperlipoproteinemia (1989) (1)
Plasma leptin levels and coronary heart disease - Response (2002) (1)
Pathophysiology of human lipoprotein receptors: clinical consequences of a cellular defect. (1984) (1)
INTENSIVE ATORVASTATIN TREATMENT REDUCES CARDIOVASCULAR EVENTS (CVE) IN THOSE WITH DYSLIPIDEMIA, CORONARY HEART DISEASE (CHD) AND WITH MILD OR MORE ADVANCED CHRONIC KIDNEY DISEASE (CKD): AN ANALYSIS OF THE TNT, IDEAL AND ALLIANCE TRIALS (2011) (0)
Reports of Societies (1975) (0)
Proceedings of the 2nd International Merck Symposium on HDL-C Raising - Bridging the gap in cardiovascular risk reduction: A call to action - Barcelona, 14-15 October, 2005 - Guest editorial (2006) (0)
What is the best way to manage dyslipidemia (2005) (0)
4.P.266 VLDL triglyceride kinetics in mixed hyperlipidaemia (1997) (0)
The pathogenesis of hyperlipoproteinaemia. (1986) (0)
Proceedings of the international Merck symposium on HDL raising beyond LDL-C reduction: New paradigms in the reduction of cardiovascular risk Rome, 1-2 October, 2004 - Introduction (2005) (0)
The low density lipoprotein receptor pathway in animals and man. (1982) (0)
Future lipid-lowering drug development : Chris J Packard Background (2001) (0)
Ezetimibe — maximising cholesterol reduction through dual inhibition (2004) (0)
Optimal strategies in preventing the next event: The role of statins in cardiovascular protection - Foreword (2003) (0)
Healthy ageing: Statin therapy opportunities - The 72nd European Atherosclerosis Society Congress - Foreword (2001) (0)
Progression and regression of atheroma. (1991) (0)
Lipoproteins and the pathogenesis of atherosclerosis : proceedings of the International Symposium on Lipoproteins and the Pathogenesis of Atherosclerosis, Gleneagles, Perthshire, 24-27 February 1991 (1991) (0)
Pravastatin reduces mortality: The Prospective Pravastatin Pooling Project (2000) (0)
Biochemical risk markers of CHD (1999) (0)
S62 New event reduction analyses from the West of Scotland study (1998) (0)
Regression ofcoronary atherosclerosis: isitpossible? (2017) (0)
Abstract 6277: Predictive Value of Estimated Glomerular Filtration Rate for Cardiovascular Events: The Treating to New Targets Study (2008) (0)
Statin therapy: a quantum advance in vascular risk management (2004) (0)
Effects of fenofibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in hypertriglyceridaemic subjects. (1985) (0)
Patients by Lipid and Nonlipid Biomarkers Prediction of Cardiovascular Events in Statin-Treated Stable Coronary (2012) (0)
Diabetic dyslipidaemia : Marc Evans and Alan Rees (2001) (0)
Pravastatin and glucose intolerance (2000) (0)
Abstract: 35 GENE VARIANTS AND PRAVASTATIN LDL LOWERING RESPONSE IN PROSPER (2009) (0)
VARIATION AT THE LDLR GENE IS ASSOCIATED WITH PLASMA LIPID LEVELS AND CHD IN THE PROSPER STUDY (2008) (0)
CHD and diabetes reversing the trend (2004) (0)
High Risk Strategies for Heart Disease Prevention (1996) (0)
Effects of insulin on very low density lipoprotein metabolism in normolipidaemic men (1995) (0)
Cross-reactivity between anti-apolipoprotein E antisera and retinal interphotoreceptor retinoid-binding protein (1988) (0)
Relative contribution of plasma small, dense LDL to coronary heart disease (CHD) risk (1995) (0)
C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Epidemiology (2007) (0)
[Antilipemic agents and postprandial lipidemia]. (1990) (0)
Chapter 29 Mode of action of lipid-lowering drugs (1997) (0)
Pragmatic coronary prevention, identifying patients at high risk of coronary heart disease (2002) (0)
Apoprotein exchange between human high-density-lipoprotein subfractions (high-density-lipoprotein subfractions 2 and 3) [proceedings]. (1978) (0)
Differential binding of LDL subfractions to human arterial proteoglycan (1995) (0)
Influence of etofibrate on human low density lipoprotein (ldl) metabolism (1987) (0)
Metabolic channelling of apolipoprotein B in very low density lipoprotein. (1984) (0)
RELATIONSHIP BETWEEN BASELINE LIPOPROTEIN PARAMETERS AND CHRONIC KIDNEY DISEASE IN CORONARY PATIENTS (2013) (0)
New aspects to the pathophysiology of diabetic dyslipidemia (1999) (0)
Separation of plasma lipoproteins in the preparative ultracentrifuge. (1980) (0)
Studies on the Mode of Action of Excess of Vitamin A 8 . MITOCHONDRIAL (2005) (0)
Mo-P5:344 Cost-effectiveness of intensive lipid-lowering treatment with atorvastatin 80MG versus 10MG in secondary cardiovascular prevention in the UK (2006) (0)
Fibrinolytic markers in pregnancy: relationship to pertubations in lipoprotein levels (1995) (0)
Drugs and high density lipoprotein metabolism. (1982) (0)
Fire-and-forget in prevention of coronary heart disease (2002) (0)
Oxidative modification of low density lipoprotein (LDL) subfractions as measured by fluorescence spectroscopy (1993) (0)
Pravastatin and glucose intolerance: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study (2000) (0)
Prediction of cardiovascular events in statin-treated patients by lipid and non-lipid biomarkers (Retraction of vol 57, pg 63, 2011) (2013) (0)
Evolving strategies in cardiovascular care: The renin-angiotensin system and the future - Discussion (2000) (0)
Pravastatin and coronary heart disease [3] (multiple letters) (1998) (0)
PO23-733 INTENSIVE ATORVASTATIN THERAPY IS ASSOCIATED WITH SIGNIFICANT CARDIOVASCULAR BENEFITS IN PATIENTS WITH AND WITHOUT CHRONIC KIDNEY DISEASE: THE TNT STUDY (2007) (0)
[Molecular pathophysiology of familial hypercholesterolemia]. (1985) (0)
Current position of ﬁbrate therapy in clinical practice : Mikko Syvänne and Marja-Riitta Taskinen (2001) (0)
Kinetic studies of apolipoprotein B(apOB) in very low density lipoproteins(VLDL) in nephrotic hyperlipidaemia (1990) (0)
Future clinical trials of lipid-lowering drugs : John C LaRosa (2001) (0)
Current concepts of monitoring and inﬂuencing coronary atherosclerosis and plaque stability in clinical practice (2001) (0)
[Classification of hyperlipoproteinemia in the light of advances in pathogenetic studies]. (1985) (0)
Metabolism of Human Triglyceride-rich Lipoprotein Remnants (1986) (0)
Association between serum concentrations of advanced glycation end products and C-reactive protein in type 2 diabetes mellitus (2003) (0)
O212 Predictive Value of Lipoprotein Parameters on the Risk of Chronic Kidney Disease in Patients with Coronary Heart Disease (2014) (0)
Lipid Metabolism and the Enterohepatic Circulation: The Regulatory Functions of HMG CoA Reductase and Cholesterol 7∝ Hydroxylase (1987) (0)
1.P.158 Identification of the most appropriate recipients of pravastatin therapy in the West of Scotland Coronary Prevention Study (WOSCOPS) cohort (1997) (0)
Dextran Sulphate Adsorption: Effects on Coronary Heart Disease (1993) (0)
Patient Data Meta-Analysis of 53 880 Subjects Mutations in the HFE Gene and Cardiovascular Disease Risk : An Individual (2008) (0)
Abnormal suppression of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by hypertriglyceridemic very low density lipoprotein subclasses (1980) (0)
Chlorophenoxyisobutyric acid derivatives and apolipoprotein B metabolism. (1985) (0)
Genetics, Drugs and Low Density Lipoprotein Metabolism (1989) (0)
Abstract: 535 CHOLESTEROL ABSORPTION AND SYNTHESIS MARKERS IN INDIVIDUALS WITH AND WITHOUT A CHD EVENT DURING PRAVASTATIN THERAPY: INSIGHTS FROM THE PROSPER TRIAL (2009) (0)
The influence of dietary-fat saturation on the metabolism of apolipoproteins A-I, B and C in a type-IIb hyperlipoproteinaemic subject [proceedings]. (1978) (0)
abetalipoproteinaemic plasma . lipoproteins in Chemical and kinetic study of the (0)
Cholesteryl ester transfer protein gene polymorphisms and high-density lipoprotein cholesterol. (1996) (0)
784 INCREASED CARDIOVASCULAR EVENT RATE IN STABLE CORONARY PATIENTS WITH METABOLIC SYNDROME COMPLICATED BY CHRONIC KIDNEY DISEASE IS REDUCED BY ATORVASTATIN (2011) (0)
New Perspectives in Human Apolipoprotein B Metabolism (1987) (0)
1.P.30 Inhibition of lipolysis in isolated rat adipocytes (1997) (0)
Lipid lowering drugs: Authors' reply (1990) (0)
Aggressive lipid lowering with atorvastatin reduces increased risk of cardiovascular events in patients with metabolic syndrome and coronary heart disease (2006) (0)
Effects of dietary-fat saturation on the composition of very-low-density lipoproteins and on the metabolism of their major apoprotein, apolipoprotein B [proceedings]. (1978) (0)
Diabetes in the West of Scotland Coronary Prevention Study Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart (2003) (0)
Receptors in the Regulation of Cholesterol Metabolism (1989) (0)
Lipid metabolism and the enterohepatic circulation: the regulatory functions of HMG CoA reductase and cholesterol 7 alpha hydroxylase. (1987) (0)
Abstract 3265: Serum Uric Acid as a Predictor of Cardiovascular Risk: The Treating to New Targets (TNT) Study (2008) (0)
PCV28 COST-EFFECTIVENESS OF INTENSIVE LIPID-LOWERING TREATMENT IN SECONDARY CARDIOVASCULAR PREVENTION IN SPAIN AND GERMANY (2006) (0)
Fibrates and Reversal of Atherogenic Particles (1992) (0)
The prognostic value for stroke of a nurse-led screening assessment of 71,527 Scottish middle-aged men (2001) (0)
Chapter 9 ApoE genotype , plasma cholesterol , and cancer : A Mendelian randomization study (2010) (0)
The effect of smoking on high density lipoprotein concentration and cholesteryl ester transfer protein activity in a healthy population (1993) (0)
The Role of Receptors in Apolipoprotein B Metabolism (1983) (0)
2.P.259 Attitudes towards coronary risk factor reduction: The HELP study (1997) (0)
Th-P16:376 ABCG5/8 and NPC1L1 polymorphisms and response to pravastatin in prosper (2006) (0)
4.P.199 VLDL subfraction metabolism during alimentary lipemia (1997) (0)
Statin therapy for the 21st century (2003) (0)
Hyperlipidaemia as a risk factor for vascular heart disease (2003) (0)
Section III: Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism? Discussion (1998) (0)
INTENSIVE LIPID LOWERING WITH ATORVASTATIN IS ASSOCIATED WITH SIGNIFICANT CARDIOVASCULAR BENEFITS IN CORONARY PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE (2008) (0)
The regulation of human low density lipoprotein subfraction distribution (1993) (0)
Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism? (1998) (0)
Lipid-lowering regimes and exercise tolerance in subjects with angina (1990) (0)
CARDIOVASCULAR EVENT RATES IN STABLE CORONARY PATIENTS WITH CHRONIC KIDNEY DISEASE, INCREASED BY THE PRESENCE OF OBESITY, ARE REDUCED BY INTENSIVE LIPID LOWERING WITH ATORVASTATIN (2010) (0)
0.S.1 Primary prevention of coronary heart disease: Whom to treat (1997) (0)
Predictors of incident diabetes in the TNT Trial (2009) (0)
Abstract: 26 HIGH-DOSE ATORVASTATIN PROVIDES SUSTAINED BENEFIT IN REDUCING RISK OF CV DISEASE AMONG STABLE CHD PATIENTS ≥65 YEARS (2009) (0)
1,2 CYCLOHEXANEDIONE (CHD)-MODIFICATION OF HUMAN VERY LOW DENSITY LIPOPROTEIN (VLDL) SLOWS ITS CONVERSION TO LOW DENSITY LIPOPROTEIN (LDL) (1981) (0)
768 CARDIOVASCULAR EVENT RATE IN STABLE CORONARY PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) INCREASED BY BEING OBESE IS REDUCED BY ATORVASTATIN (2011) (0)
1.P.159 Assessment of liver function monitoring in the West of Scotland Coronary Prevention Study (WOSCOPS) (1997) (0)
The assessment of plasma lipoprotein metabolism in the cat (Felis domesticus) (1994) (0)
2.P.271 High plasma Lp(a) levels and low plasma HDL-cholesterol levels as risk factors for cerebrovascular disease in elderly men and women (1997) (0)
212: Intensive Lipid Lowering With Atorvastatin is Associated With Significant Cardiovascular Benefits in Patients With and Without Chronic Kidney Disease (2007) (0)
A comparison of two methods to investigate the metabolism of human apolipoproteins A-I and and A-I 1 (2002) (0)
Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice? (1998) (0)
INCREASED CARDIOVASCULAR EVENT RATE OBSERVED IN STABLE CORONARY PATIENTS WITH METABOLIC SYNDROME COMPLICATED BY CHRONIC KIDNEY DISEASE IS REDUCED BY INTENSIVE LIPID LOWERING WITH ATORVASTATIN (2010) (0)
Pharmacologic modulation of the low density lipoprotein receptor pathway. (1988) (0)
Coronary heart disease telephone helpline: What the public want to know (1995) (0)
214: Effect of Intensive Cholesterol Lowering With Atorvastatin in Patients with Previous Coronary Bypass Surgery: A Treating to New Targets (TNT) Substudy (2007) (0)
Urinary Mevalonic Acid and Plasma Lathosterol: Responses to Simvastatin Therapy (1992) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With J. B. Shepherd?

J. B. Shepherd is affiliated with the following schools: